Movement Alert｜AstraZeneca Rises 3.07% in Regular Trading, $1.5 Billion Lung Cancer Drug Licensing Deal Boosts Sentiment

Market Focus07-15 23:55

On July 15, AstraZeneca rose 3.07% in regular trading, trading at $169.575/share, with turnover of $175 million. The rally was driven by the company's announcement of a global exclusive licensing agreement with Dizal Pharmaceutical to develop and commercialize lung cancer drug Zegfrovy in a deal worth up to $1.5 billion.

Under the agreement announced on July 14, AstraZeneca will pay $600 million upfront to acquire global development and commercialization rights for the targeted therapy. The deal strengthens AstraZeneca's oncology portfolio and partially restores investor confidence following its stock decline of approximately 9% on July 9, when its jointly developed cardiac drug Wainua failed to meet the primary endpoint in a Phase III trial.

However, Dizal Pharmaceutical issued a notice on July 15 highlighting uncertainties surrounding the agreement's effectiveness, noting it remains subject to shareholder approval and overseas antitrust review. Separately, AstraZeneca recently entered a siRNA drug collaboration with CSPC Pharmaceutical worth up to $1.77 billion, signaling an accelerating pace of external pipeline acquisitions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178864561?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 23:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178864561","market":"hk","top_or_hot":-1,"title":"Movement Alert｜AstraZeneca Rises 3.07% in Regular Trading, $1.5 Billion Lung Cancer Drug Licensing Deal Boosts Sentiment","media":"Market Focus","content":"<p><p>On July 15, AstraZeneca rose 3.07% in regular trading, trading at $169.575/share, with turnover of $175 million. The rally was driven by the company's announcement of a global exclusive licensing agreement with Dizal Pharmaceutical to develop and commercialize lung cancer drug Zegfrovy in a deal worth up to $1.5 billion.</p><p>Under the agreement announced on July 14, AstraZeneca will pay $600 million upfront to acquire global development and commercialization rights for the targeted therapy. The deal strengthens AstraZeneca's oncology portfolio and partially restores investor confidence following its stock decline of approximately 9% on July 9, when its jointly developed cardiac drug Wainua failed to meet the primary endpoint in a Phase III trial.</p><p>However, Dizal Pharmaceutical issued a notice on July 15 highlighting uncertainties surrounding the agreement's effectiveness, noting it remains subject to shareholder approval and overseas antitrust review. Separately, AstraZeneca recently entered a siRNA drug collaboration with CSPC Pharmaceutical worth up to $1.77 billion, signaling an accelerating pace of external pipeline acquisitions.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AstraZeneca Rises 3.07% in Regular Trading, $1.5 Billion Lung Cancer Drug Licensing Deal Boosts Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AstraZeneca Rises 3.07% in Regular Trading, $1.5 Billion Lung Cancer Drug Licensing Deal Boosts Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 23:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, AstraZeneca rose 3.07% in regular trading, trading at $169.575/share, with turnover of $175 million. The rally was driven by the company's announcement of a global exclusive licensing agreement with Dizal Pharmaceutical to develop and commercialize lung cancer drug Zegfrovy in a deal worth up to $1.5 billion.</p><p>Under the agreement announced on July 14, AstraZeneca will pay $600 million upfront to acquire global development and commercialization rights for the targeted therapy. The deal strengthens AstraZeneca's oncology portfolio and partially restores investor confidence following its stock decline of approximately 9% on July 9, when its jointly developed cardiac drug Wainua failed to meet the primary endpoint in a Phase III trial.</p><p>However, Dizal Pharmaceutical issued a notice on July 15 highlighting uncertainties surrounding the agreement's effectiveness, noting it remains subject to shareholder approval and overseas antitrust review. Separately, AstraZeneca recently entered a siRNA drug collaboration with CSPC Pharmaceutical worth up to $1.77 billion, signaling an accelerating pace of external pipeline acquisitions.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"","article_id":"1178864561","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178864561","pubTimestamp":1784130941,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, AstraZeneca rose 3.07% in regular trading, trading at $169.575/share, with turnover of $175 million. The rally was driven by the company's announcement of a global exclusive licensing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"走势提醒|阿斯利康常规交易上涨3.07%，15亿美元肺癌药物许可协议提振市场情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"On July 15, AstraZeneca rose 3.07% in regular trading, trading at $169.575/share, with turnover of $175 million. The rally was driven by the company's announcement of a global exclusive licensing agreement with Dizal Pharmaceutical to develop and commercialize lung cancer drug Zegfrovy in a deal worth up to $1.5 billion.Under the agreement announced on July 14, AstraZeneca will pay $600 million upfront to acquire global development and commercialization rights for the targeted therapy. The deal strengthens AstraZeneca's oncology portfolio and partially restores investor confidence following its stock decline of approximately 9% on July 9, when its jointly developed cardiac drug Wainua failed to meet the primary endpoint in a Phase III trial.However, Dizal Pharmaceutical issued a notice on July 15 highlighting uncertainties surrounding the agreement's effectiveness, noting it remains subject to shareholder approval and overseas antitrust review. Separately, AstraZeneca recently entered a siRNA drug collaboration with CSPC Pharmaceutical worth up to $1.77 billion, signaling an accelerating pace of external pipeline acquisitions.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178864561","isCrawlerRequest":true}